MAGE-4 (169-177)

MAGE-4 (169-177) is a synthetic peptide corresponding to amino acids 169 through 177 of the melanoma-associated antigen 4 (MAGE-4) protein. As a member of the MAGE family, this peptide represents a highly conserved epitope involved in tumor antigenicity and immune recognition. Its defined sequence, derived from a region known for immunogenic potential, makes it a valuable tool for studies focused on antigen presentation, tumor immunology, and peptide-based assay development. The peptide's stability and sequence specificity enable researchers to investigate cellular immune responses and peptide-MHC interactions in a controlled experimental setting.

Epitope mapping: In immunological research, the 169-177 fragment of MAGE-4 serves as a critical reagent for precise epitope mapping. By incorporating this peptide into in vitro assays, scientists can delineate the regions of MAGE-4 recognized by cytotoxic T lymphocytes or other immune effectors. Such mapping is instrumental for understanding the molecular determinants of immune recognition in tumor environments and for identifying minimal antigenic determinants suitable for further study or therapeutic design.

T cell activation studies: The defined sequence of this peptide enables its use in assays aimed at evaluating antigen-specific T cell responses. Researchers commonly employ it to load antigen-presenting cells or use it directly in ELISPOT, intracellular cytokine staining, or proliferation assays. These applications facilitate the assessment of T cell activation, cytokine production, and cytolytic potential in response to MAGE-4-derived epitopes, thereby supporting the development of immunological models and the validation of peptide-specific immune responses.

Peptide-MHC binding assays: The 169-177 peptide is well-suited for investigating its affinity and stability in binding to major histocompatibility complex (MHC) molecules, particularly class I MHC. Such studies are essential for elucidating the peptide's immunodominance and for characterizing the molecular interactions that underpin antigen presentation. The ability to assess binding kinetics and stability provides valuable data for immunogen design and for the optimization of peptide-based vaccine candidates.

Immunoassay development: The unique sequence and immunological relevance of this peptide make it a preferred standard in the development and validation of immunoassays. It is frequently utilized as a positive control or calibration standard in ELISA, flow cytometry, and other peptide-based detection systems. These applications are crucial for ensuring assay sensitivity, specificity, and reproducibility when measuring MAGE-4-specific immune responses or screening for immune-reactive cell populations.

Peptide library screening: In the context of high-throughput screening and combinatorial library approaches, the MAGE-4 (169-177) peptide can be incorporated into peptide arrays or libraries to probe antibody or T cell receptor specificity. This strategy enables the identification of cross-reactive epitopes, the assessment of immune repertoire diversity, and the discovery of novel immunogenic sequences related to MAGE family antigens. Such applications enhance the understanding of antigenic landscapes and inform the rational design of next-generation immunological reagents.

1. Genetic, cellular, and structural characterization of the membrane potential-dependent cell-penetrating peptide translocation pore

2. High fat diet and GLP-1 drugs induce pancreatic injury in mice

3. TMEM16F and dynamins control expansive plasma membrane reservoirs

4. Emu oil in combination with other active ingredients for treating skin imperfections

5. Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma